Haemonetics Corp (HAE) 34.50 $HAE
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 34.50 (+0.98), NUVA: 62.50 (-0.79)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 34.50 (+0.98)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 34.50 (+0.98)
Haemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016
PR Newswire - Mon Jul 18, 4:19PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that the Company will publish fiscal year 2017 first quarter financial results at 6:00am Eastern Time on Monday, August 1, 2016. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on August 1, 2016.
HAE: 34.50 (+0.98)
Watch for Haemonetics to Potentially Rebound After Falling 2.17% Yesterday
Comtex SmarTrend(R) - Fri Jul 15, 4:32PM CDT
Haemonetics (NYSE:HAE) traded in a range yesterday that spanned from a low of $29.76 to a high of $30.70. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $29.98 on volume of 178,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
HAE: 34.50 (+0.98)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 24.10 (-0.33), HAE: 34.50 (+0.98), BAX: 48.29 (-0.21), LMAT: 17.26 (-0.63)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 34.50 (+0.98)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 34.50 (+0.98)
Upgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue May 17, 3:13AM CDT
Haemonetics (NYSE:HAE) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $27.73 on volume of 586,000 shares, above average daily volume of 408,000. In the past 52 weeks, shares of Haemonetics have traded between a low of $25.98 and a high of $43.85 and closed yesterday at $27.73, which is 7% above that low price. The 200-day and 50-day moving averages have moved 0.68% lower and 0.96% lower over the past week, respectively.
HAE: 34.50 (+0.98)
Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer
PR Newswire - Mon May 09, 4:00PM CDT
Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
HAE: 34.50 (+0.98)
Why Baidu, Pandora Media, and Haemonetics Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 02, 4:45PM CDT
Monday was a positive day on Wall Street, and the stock market bounced back from losses to close last week. The Dow picked up a triple-digit daily gain, and most broad-based market benchmarks rose between 0.75% and 1% on the day. Somewhat...
BIDU: 161.36 (-1.87), P: 13.05 (-0.45), HAE: 34.50 (+0.98)
Haemonetics reports 4Q loss
Automated Insights - Mon May 02, 5:31AM CDT
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported a loss of $8.8 million in its fiscal fourth quarter.
HAE: 34.50 (+0.98)
Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported
PR Newswire - Mon May 02, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%. Revenue was up 10% over the fourth quarter of fiscal 2015 in constant currency, benefiting by 6.8% from the inclusion of a 53rd week.
HAE: 34.50 (+0.98)
Haemonetics Honored for Delivering 'World-Class' Customer Service
PR Newswire - Fri Apr 29, 11:01AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that it has received the NorthFace ScoreBoard AwardSM from Omega Management Group Corp. in recognition of achieving excellence in customer service and support in 2015. This marks the sixteenth consecutive year that Haemonetics has earned this high honor. Since 2000, the award has been presented annually to companies who, as rated solely by their own customers, exceeded expectations in customer satisfaction during the prior calendar year. Omega is an expert in customer experience management (CEM) strategy, and helps companies boost revenue and profits by consistently exceeding customer expectations for service quality.
HAE: 34.50 (+0.98)
Haemonetics Announces CFO's Retirement
PR Newswire - Thu Apr 14, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development has announced his retirement from Haemonetics Corporation effective May 27, 2016. The Company announced it will immediately begin a search for Mr. Lindop's successor.
HAE: 34.50 (+0.98)
Haemonetics Sets Date for Investor/Analyst Meeting - May 10, 2016
PR Newswire - Tue Apr 05, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced today that it will host its annual investor and analyst meeting on Tuesday, May 10th from 9:00am to 2:30pm at The State Room, 60 State Street in Boston, Massachusetts.
HAE: 34.50 (+0.98)
Haemonetics Tops Q3 Earnings, Lags Revenues; Keeps View
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 10:10AM CST
Haemonetics (HAE) delivered a mixed third-quarter fiscal 2016 performance
CSII: 19.44 (-0.06), HAE: 34.50 (+0.98), LMAT: 17.26 (-0.63), VASC: 45.53 (-0.92)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 34.50 (+0.98), NUVA: 62.50 (-0.79)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 34.50 (+0.98)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 34.50 (+0.98)
Haemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016
PR Newswire - Mon Jul 18, 4:19PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that the Company will publish fiscal year 2017 first quarter financial results at 6:00am Eastern Time on Monday, August 1, 2016. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on August 1, 2016.
HAE: 34.50 (+0.98)
Watch for Haemonetics to Potentially Rebound After Falling 2.17% Yesterday
Comtex SmarTrend(R) - Fri Jul 15, 4:32PM CDT
Haemonetics (NYSE:HAE) traded in a range yesterday that spanned from a low of $29.76 to a high of $30.70. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $29.98 on volume of 178,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
HAE: 34.50 (+0.98)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 24.10 (-0.33), HAE: 34.50 (+0.98), BAX: 48.29 (-0.21), LMAT: 17.26 (-0.63)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 34.50 (+0.98)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 34.50 (+0.98)
Upgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue May 17, 3:13AM CDT
Haemonetics (NYSE:HAE) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $27.73 on volume of 586,000 shares, above average daily volume of 408,000. In the past 52 weeks, shares of Haemonetics have traded between a low of $25.98 and a high of $43.85 and closed yesterday at $27.73, which is 7% above that low price. The 200-day and 50-day moving averages have moved 0.68% lower and 0.96% lower over the past week, respectively.
HAE: 34.50 (+0.98)
Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer
PR Newswire - Mon May 09, 4:00PM CDT
Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
HAE: 34.50 (+0.98)
Why Baidu, Pandora Media, and Haemonetics Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 02, 4:45PM CDT
Monday was a positive day on Wall Street, and the stock market bounced back from losses to close last week. The Dow picked up a triple-digit daily gain, and most broad-based market benchmarks rose between 0.75% and 1% on the day. Somewhat...
BIDU: 161.36 (-1.87), P: 13.05 (-0.45), HAE: 34.50 (+0.98)
Haemonetics reports 4Q loss
Automated Insights - Mon May 02, 5:31AM CDT
BRAINTREE, Mass. (AP) _ Haemonetics Corp. (HAE) on Monday reported a loss of $8.8 million in its fiscal fourth quarter.
HAE: 34.50 (+0.98)
Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported
PR Newswire - Mon May 02, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%. Revenue was up 10% over the fourth quarter of fiscal 2015 in constant currency, benefiting by 6.8% from the inclusion of a 53rd week.
HAE: 34.50 (+0.98)
Haemonetics Honored for Delivering 'World-Class' Customer Service
PR Newswire - Fri Apr 29, 11:01AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that it has received the NorthFace ScoreBoard AwardSM from Omega Management Group Corp. in recognition of achieving excellence in customer service and support in 2015. This marks the sixteenth consecutive year that Haemonetics has earned this high honor. Since 2000, the award has been presented annually to companies who, as rated solely by their own customers, exceeded expectations in customer satisfaction during the prior calendar year. Omega is an expert in customer experience management (CEM) strategy, and helps companies boost revenue and profits by consistently exceeding customer expectations for service quality.
HAE: 34.50 (+0.98)
Haemonetics Announces CFO's Retirement
PR Newswire - Thu Apr 14, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development has announced his retirement from Haemonetics Corporation effective May 27, 2016. The Company announced it will immediately begin a search for Mr. Lindop's successor.
HAE: 34.50 (+0.98)
Haemonetics Sets Date for Investor/Analyst Meeting - May 10, 2016
PR Newswire - Tue Apr 05, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced today that it will host its annual investor and analyst meeting on Tuesday, May 10th from 9:00am to 2:30pm at The State Room, 60 State Street in Boston, Massachusetts.
HAE: 34.50 (+0.98)
Haemonetics Tops Q3 Earnings, Lags Revenues; Keeps View
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 10:10AM CST
Haemonetics (HAE) delivered a mixed third-quarter fiscal 2016 performance
CSII: 19.44 (-0.06), HAE: 34.50 (+0.98), LMAT: 17.26 (-0.63), VASC: 45.53 (-0.92)
